163 related articles for article (PubMed ID: 38013436)
21. Antimicrobial peptides for novel antiviral strategies in the current post-COVID-19 pandemic.
Loffredo MR; Nencioni L; Mangoni ML; Casciaro B
J Pept Sci; 2024 Jan; 30(1):e3534. PubMed ID: 37501572
[TBL] [Abstract][Full Text] [Related]
22. Temporin G, an amphibian antimicrobial peptide against influenza and parainfluenza respiratory viruses: Insights into biological activity and mechanism of action.
De Angelis M; Casciaro B; Genovese A; Brancaccio D; Marcocci ME; Novellino E; Carotenuto A; Palamara AT; Mangoni ML; Nencioni L
FASEB J; 2021 Feb; 35(2):e21358. PubMed ID: 33538061
[TBL] [Abstract][Full Text] [Related]
23. Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus.
Kozhikhova KV; Shilovskiy IP; Shatilov AA; Timofeeva AV; Turetskiy EA; Vishniakova LI; Nikolskii AA; Barvinskaya ED; Karthikeyan S; Smirnov VV; Kudlay DA; Andreev SM; Khaitov MR
J Mater Chem B; 2020 Apr; 8(13):2607-2617. PubMed ID: 32124885
[TBL] [Abstract][Full Text] [Related]
24. Antiviral peptides as promising therapeutic drugs.
Vilas Boas LCP; Campos ML; Berlanda RLA; de Carvalho Neves N; Franco OL
Cell Mol Life Sci; 2019 Sep; 76(18):3525-3542. PubMed ID: 31101936
[TBL] [Abstract][Full Text] [Related]
25. Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses.
Tampere M; Pettke A; Salata C; Wallner O; Koolmeister T; Cazares-Körner A; Visnes T; Hesselman MC; Kunold E; Wiita E; Kalderén C; Lightowler M; Jemth AS; Lehtiö J; Rosenquist Å; Warpman-Berglund U; Helleday T; Mirazimi A; Jafari R; Puumalainen MR
Viruses; 2020 Dec; 12(12):. PubMed ID: 33322045
[TBL] [Abstract][Full Text] [Related]
26. Study on Antiviral Activity of Two Recombinant Antimicrobial Peptides Against Tobacco Mosaic Virus.
Sabokkhiz MA; Tanhaeian A; Mamarabadi M
Probiotics Antimicrob Proteins; 2019 Dec; 11(4):1370-1378. PubMed ID: 30887308
[TBL] [Abstract][Full Text] [Related]
27. [Peptides--a new strategy for combating viral infections].
Kołodziej M; Joniec J; Bartoszcze M; Mirski T; Gryko R
Przegl Epidemiol; 2011; 65(3):477-82. PubMed ID: 22184952
[TBL] [Abstract][Full Text] [Related]
28. Antiviral Peptides Targeting the Helicase Activity of Enterovirus Nonstructural Protein 2C.
Fang Y; Wang C; Wang C; Yang R; Bai P; Zhang XY; Kong J; Yin L; Qiu Y; Zhou X
J Virol; 2021 May; 95(12):. PubMed ID: 33789997
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of influenza virus replication by Apiaceae plants, with special reference to Peucedanum japonicum (Sacna) constituents.
Kanazawa R; Morimoto R; Horio Y; Sumitani H; Isegawa Y
J Ethnopharmacol; 2022 Jun; 292():115243. PubMed ID: 35358620
[TBL] [Abstract][Full Text] [Related]
30. Antiviral Activities of Human Host Defense Peptides.
Brice DC; Diamond G
Curr Med Chem; 2020; 27(9):1420-1443. PubMed ID: 31385762
[TBL] [Abstract][Full Text] [Related]
31. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs.
Witvrouw M; De Clercq E
Gen Pharmacol; 1997 Oct; 29(4):497-511. PubMed ID: 9352294
[TBL] [Abstract][Full Text] [Related]
32. A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses.
Sample CJ; Hudak KE; Barefoot BE; Koci MD; Wanyonyi MS; Abraham S; Staats HF; Ramsburg EA
Peptides; 2013 Oct; 48():96-105. PubMed ID: 23891650
[TBL] [Abstract][Full Text] [Related]
33. The antimicrobial peptide HS-1 inhibits dengue virus infection.
Monteiro JMC; Oliveira MD; Dias RS; Nacif-Marçal L; Feio RN; Ferreira SO; Oliveira LL; Silva CC; Paula SO
Virology; 2018 Jan; 514():79-87. PubMed ID: 29153860
[TBL] [Abstract][Full Text] [Related]
34. Antiviral activity of phytochemicals: a comprehensive review.
Naithani R; Huma LC; Holland LE; Shukla D; McCormick DL; Mehta RG; Moriarty RM
Mini Rev Med Chem; 2008 Oct; 8(11):1106-33. PubMed ID: 18855727
[TBL] [Abstract][Full Text] [Related]
35. Activity of two synthetic amphiphilic peptides and magainin-2 against herpes simplex virus types 1 and 2.
Aboudy Y; Mendelson E; Shalit I; Bessalle R; Fridkin M
Int J Pept Protein Res; 1994 Jun; 43(6):573-82. PubMed ID: 7928088
[TBL] [Abstract][Full Text] [Related]
36. Current progress in antiviral strategies.
Lou Z; Sun Y; Rao Z
Trends Pharmacol Sci; 2014 Feb; 35(2):86-102. PubMed ID: 24439476
[TBL] [Abstract][Full Text] [Related]
37. Isopeptide Bond Bundling Superhelix for Designing Antivirals against Enveloped Viruses with Class I Fusion Proteins: A Review.
Na H; Liang G; Lai W
Curr Pharm Biotechnol; 2023; 24(14):1774-1783. PubMed ID: 37005549
[TBL] [Abstract][Full Text] [Related]
38. Animal venoms as a source of antiviral peptides active against arboviruses: a systematic review.
Lima WG; Maia CQ; de Carvalho TS; Leite GO; Brito JCM; Godói IPD; de Lima ME; Ferreira JMS
Arch Virol; 2022 Sep; 167(9):1763-1772. PubMed ID: 35723756
[TBL] [Abstract][Full Text] [Related]
39. Chemically modified antiviral peptides against SARS-CoV-2.
Quagliata M; Papini AM; Rovero P
J Pept Sci; 2024 Feb; 30(2):e3541. PubMed ID: 37699615
[TBL] [Abstract][Full Text] [Related]
40. Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of
Jackson JW; Hancock TJ; Dogra P; Patel R; Arav-Boger R; Williams AD; Kennel SJ; Wall JS; Sparer TE
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
